Increase in prescription dispensing
First written in FY2018-Q1. 16 of 25 entries say "Advanced", first in FY2019. Latest entry: FY2027-H1.
No other company in this theme has enough history to compare yet.
- FY2027-H1AdvancedAnnual report
「In the pharmacy business, the company renovated dispensing areas and waiting rooms, strengthened its capacity to handle highly specialized prescriptions and home-visit pharmacy services by deepening cooperation with medical institutions, and strengthened prescription acquisition by reviewing business hours and taking other measures.」
To increase prescriptions accepted, the company is pursuing specific measures including renovation of pharmacy space, cooperation with medical institutions, support for highly specialized prescriptions and home-visit pharmacy services, and revised business hours. - FY2026-H1AdvancedAnnual report
「The Group proceeded with the expansion and refurbishment of dispensing rooms and waiting areas and strengthened its capacity to fill prescriptions requiring a high level of expertise, thereby increasing the number of affiliated medical institutions and expanding its revenue base.」
To increase prescriptions accepted, the company describes measures to establish a service structure for highly specialized prescriptions and increase the number of affiliated medical institutions. - FY2025AdvancedAnnual report
「As the population aged, prescription volumes in the pharmacy business grew, and the performance of each company remained strong.」
The increase in prescriptions accepted is described as a result of population aging and growth in the pharmacy business. - FY2025-H1RestatedAnnual report
「In the pharmacy business, the company expanded and renovated dispensing areas and pharmacy waiting rooms to accommodate rising prescription volumes, while working to increase the acquisition of prescriptions requiring a higher level of expertise and strengthen the pharmacy business's sales base.」
The company continues to address rising prescription volumes and increase the acquisition of prescriptions requiring a higher level of expertise. - FY2025-Q1RestatedAnnual report
「In the pharmacy business, the company pursued new pharmacy openings and sought to further expand its market share by expanding and renovating dispensing areas and pharmacy waiting rooms to accommodate rising prescription volumes.」
To increase prescriptions accepted, the company is pursuing new pharmacy openings and expansion and renovation of dispensing areas and waiting rooms, with a goal of further increasing market share. - FY2024-Q3RestatedAnnual report
「The company also sought to improve the quality of patient-facing services by strengthening pharmacists' specialized training, while working to increase the acquisition of high-value prescriptions and strengthen the pharmacy business's sales base.」
The company continues to strengthen patient-facing services through pharmacist education and acquire high-value prescriptions in order to expand prescriptions accepted and pharmacy sales. - FY2024-Q2AdvancedAnnual report
「In addition, we sought to advance customer-facing services by strengthening pharmacists' specialist training, while working to attract prescriptions for high-priced medicines.」
To increase prescriptions accepted, the company explicitly identifies strengthening pharmacists' patient-facing services through education and acquiring high-value prescriptions as measures. - FY2024-Q1AdvancedAnnual report
「Sales-enhancement measures included further promoting downloads of the family pharmacy app, whose user base has exceeded 1 million, and expanding and renovating dispensing areas and pharmacy waiting rooms.」
The family pharmacy app surpassed 1 million users, and the company is expanding pharmacy use by promoting app usage and expanding pharmacy space. - FY2023AdvancedAnnual report
「The main factors behind the increase included business expansion following the opening of 107 new stores, comprising 32 stores in Kanto, 33 in Chubu, 8 in Hokuriku and 34 in Kansai; higher pharmacy sales resulting from a 10.1% year-on-year increase in prescription volumes, supported by the increase in stores providing pharmacy services; and higher sales of related products due to the renewed spread of COVID-19 and other factors.」
Prescription volumes increased 10.1% year on year, marking a new record for growth in prescriptions accepted, supported by new store openings and the increase in stores providing pharmacy services. - FY2023-Q3AdvancedAnnual report
「The company pursued new pharmacy openings, stronger sales efforts targeting nearby medical institutions, expansion and renovation of dispensing areas and pharmacy waiting rooms to accommodate rising prescription volumes, and improved patient convenience through the OEM provision of a medication notebook app.」
To increase prescriptions accepted, the company is pursuing new pharmacy openings, sales efforts targeting nearby medical institutions, expansion of pharmacy space, and offering the app on an OEM basis. - FY2023-Q2AdvancedAnnual report
「Against this backdrop, to expand the dispensing business, the Group proceeded with new pharmacy openings and worked to strengthen in-store and app-based communications with retail customers to increase dispensing service use, expand and refurbish dispensing rooms and waiting areas to handle the growing number of prescriptions filled, and promote task shifting from pharmacists to medical administrative staff to improve productivity.」
To increase prescriptions accepted, the company is pursuing new pharmacy openings, stronger in-store and app-based promotion, expansion and renovation of pharmacy space, and task shifting. - FY2023-Q1AdvancedAnnual report
「To strengthen the pharmacy business, measures to boost sales include promoting downloads of the family pharmacy app and expanding and renovating dispensing areas and pharmacy waiting rooms, in addition to」
To increase prescriptions accepted and pharmacy use, the company is promoting use of its family pharmacy app and expanding and renovating dispensing areas and waiting rooms. - FY2022-Q3AdvancedAnnual report
「To further expand the dispensing business, the Group proceeded with new pharmacy openings and worked to expand and refurbish dispensing rooms and waiting areas, strengthen communications to increase dispensing service use, promote downloads of its family pharmacy app, and actively recruit pharmacists.」
To increase prescriptions accepted and pharmacy use, the company is pursuing new pharmacy openings, expansion of pharmacy space, promotional activities, app initiatives and pharmacist recruitment. - FY2022-Q2AdvancedAnnual report
「Against this backdrop, in the dispensing business, the Group proceeded with new pharmacy openings and worked to further expand the dispensing business and improve productivity by strengthening in-store and app-based communication with retail customers to increase the rate of combined dispensing service use, and by expanding and refurbishing dispensing rooms and waiting areas.」
To increase prescriptions accepted, the company explicitly identifies new pharmacy openings, stronger in-store and app-based promotion, and a higher rate of combined pharmacy use as measures. - FY2022-Q1AdvancedAnnual report
「Higher prescription volumes from new pharmacy openings and efficiency gains from the introduction of pharmacy equipment」
To increase prescriptions accepted, the company explicitly identifies new pharmacy openings as a means and is also pursuing efficiency gains through the introduction of pharmacy equipment. - FY2021Prescription volumes increased, but growth slowedAnnual report
「The increase in pharmacy sales was also attributable in part to the 2.7% year-on-year increase in prescription volumes, supported by the increase in the number of stores providing pharmacy services.」
Prescription volumes increased 2.7% year on year, but the rate of increase slowed from the 13.1% growth reported for the previous fiscal year. - FY2021-Q2Decline in prescription volumes due to patients deferring medical consultationsAnnual report
「Decline in prescription volumes due to patients deferring medical consultations amid the spread of COVID-19」
For the theme of increasing prescriptions accepted, the company reported a decline in prescription volumes during the quarter as patients deferred medical consultations against the backdrop of the infectious disease. - FY2020AdvancedAnnual report
「Pharmacy sales also increased as a result of the 13.1% year-on-year increase in prescription volumes.」
Independently of changes in the unit price per prescription, prescription volumes increased 13.1% year on year. - FY2019AdvancedAnnual report
「Net sales for the consolidated fiscal year were ¥488.464 billion, up 6.9% year on year, or ¥31.417 billion. The main factors behind the increase were higher merchandise sales due to 102 new store openings, comprising 31 stores in Kanto, 31 in Chubu and 40 in Kansai, and solid growth at existing stores, as well as higher pharmacy sales resulting from a 12.9% increase in prescription volumes, despite a 4.1% year-on-year decline in the unit price per prescription following the revision of medical service fees.」
While the unit price per prescription declined 4.1%, prescription volumes increased 12.9%, demonstrating progress toward the goal of increasing prescriptions accepted. - FY2018RestatedAnnual report
「Measures to increase the number of prescriptions filled, including promoting the use of generic drugs by expanding the range of generic products handled, conducting education on specific diseases in cooperation with government and medical institutions, and strengthening the provision of centralized medication-information management services using medication notebooks」
The company continues to aim for higher prescription volumes through generic drugs, education on specific diseases, and medication information management services. - FY2018-Q3RestatedAnnual report
「Measures to increase the number of prescriptions filled, including promoting the use of generic drugs, strengthening education on specific diseases, and enhancing the provision of centralized medication-information management services」
The company continues to pursue its goal of increasing prescription volumes through the use of generic drugs, education on specific diseases, and centralized medication information management services. - FY2018-Q2RestatedAnnual report
「Measures to increase the number of prescriptions filled, including promoting the use of generic drugs, strengthening education on specific diseases, and enhancing the provision of centralized medication-information management services」
The company continues to pursue its goal of increasing prescription volumes through the use of generic drugs, education on specific diseases, and centralized medication information management services. - FY2018-Q1First statedAnnual report
「Initiatives aimed at increasing prescriptions accepted」
It sets an explicit goal of increasing prescriptions accepted and identifies collaboration with government and medical institutions and medication information management services as means of achieving it.